

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/765,926	01/29/2004	Baldomero M. Olivera	2314-273	2903
6449	7590 06/06/2006		EXAMINER	
ROTHWELL, FIGG, ERNST & MANBECK, P.C.			HAMIDINIA, SHAWN A	
1425 K STR SUITE 800	EI, N.W.		ART UNIT	PAPER NUMBER
WASHING	ΓΟN, DC 20005	1653		
			DATE MAILED: 06/06/200	6

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/765,926	OLIVERA ET AL.				
Office Action Summary	Examiner	Art Unit				
	Shawn Hamidinia	1653				
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet w	ith the correspondence address				
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D.  - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period.  - Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNION 136(a). In no event, however, may a rewill apply and will expire SIX (6) MON e, cause the application to become AE	CATION. reply be timely filed ITHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 29 J	· · · · · · · · · · · · · · · · · · ·					
·—	•—					
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
closed in accordance with the practice under	Ex parte Quayle, 1935 C.L	0. 11, 453 O.G. 213.				
Disposition of Claims						
<ul> <li>4) ⊠ Claim(s) 1-15 is/are pending in the application 4a) Of the above claim(s) is/are withdra</li> <li>5) ☐ Claim(s) is/are allowed.</li> <li>6) ☐ Claim(s) is/are rejected.</li> <li>7) ☐ Claim(s) is/are objected to.</li> <li>8) ⊠ Claim(s) 1-15 are subject to restriction and/or</li> </ul>	awn from consideration.					
Application Papers						
9) The specification is objected to by the Examination 10) The drawing(s) filed on is/are: a) acceptable and applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examination is objected.	cepted or b) objected to e drawing(s) be held in abeyar ction is required if the drawing	nce. See 37 CFR 1.85(a). i(s) is objected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Bureat * See the attached detailed Office action for a list	nts have been received. Its have been received in Apprity documents have been au (PCT Rule 17.2(a)).	Application No I received in this National Stage				
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08 Paper No(s)/Mail Date	Paper No(	Summary (PTO-413) s)/Mail Date Informal Patent Application (PTO-152)				

Application/Control Number: 10/765,926 Page 2

Art Unit: 1653

## **DETAILED ACTION**

## Election/Restrictions

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1-2 and 5, drawn to an isolated peptide, classified in class 514, subclass 12.
- II. Claims 3-4, drawn to an isolated nucleic acid, classified in class 536, subclass 23.1
- III. Claims 6-15, drawn to a method for treating or preventing disorders associated with voltage gated ion channels, classified in class 514, subclass 12.
- 2. The polynucleotides of Group II are related to the polypeptides of Group I by virtue of the fact that polynucleotides codes for the protein. The polynucleotides have utility for the recombinant production of the protein in a host cell. Although the polynucleotide and the protein are related, since the polynucleotide encodes the specifically claimed protein, they are distinct inventions because the protein product can be made by other and materially distinct processes, such as purification from the natural source. Further, polynucleotides can be used for processes other than the production of protein, such as nucleic acid hybridization assays.
- 3. The polypeptides of Groups I are related to the methods of Groups III as product and process of use. The inventions can be distinct if either or both of the following can

Application/Control Number: 10/765,926 Page 3

Art Unit: 1653

be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the polypeptides of Groups I can be used in a method of making an antibody or in activity assays which are materially different methods than a method for treating patients with voltage gated ion channel disorders.

## Restriction Requirement Applicable to all Groups

4. Furthermore, in claims 1-15 the presence of multiple polypeptide sequences, each with a different SEQ ID NO: allows for a variety of patentably distinct products. Depending on the sequence of each polypeptide, the characteristics of the resulting molecule will vary in regards to structure and function. Each one of these polypeptides is capable of eliciting a specific immune response and can be used to produce a specific antibody. Therefore these polypeptides are patentably distinct absent factual evidence to the contrary. Applicant is required under 35 U.S.C. 121 to elect a single SEQ ID NO: for prosecution on the merits.

Applicant is advised that a reply to this requirement must include an identification of SEQ ID NO: that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. The applicant should be aware that selection of a single SEQ ID NO: represents a response to a restriction requirement, **not an election of species.** 

Application/Control Number: 10/765,926

Art Unit: 1653

5. Having shown that these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and recognized divergent subject matter as defined by MPEP § 808.02, the Examiner has prima facie shown a serious burden of search (see MPEP § 803).

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shawn Hamidinia whose telephone number is (571) 272-4534. The examiner can normally be reached on Mon-Fri from 9:00 a.m. to 5:00 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon Weber can be reached on (571) 272-0925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

SAH

ROBERT A. WAX

Page 4